19:14 , Nov 17, 2016 |  BC Innovations  |  Translation in Brief

Hormones in harness

A compound that brings together the therapeutic benefits of glucagon (GCG) and triiodothyronine (T3) could treat multiple metabolic diseases without courting the off-target toxicities associated with the individual hormones. In a Cell study published last...
07:00 , May 6, 2013 |  BioCentury  |  Strategy

Doubling down in diabetes

Against a backdrop of flattening sales of its only marketed diabetes drugs and a new class of oral drugs - SGLT2s - entering the market from competitors, Merck & Co. Inc. appears to be shoring...
08:00 , Nov 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Glucagon-like peptide-1 receptor (GLP-1R; GLP1R); estrogen receptor In vitro and mouse studies identified a stable GLP-1-estrogen conjugate that could help treat type 2...
08:00 , Feb 6, 2012 |  BioCentury  |  Finance

Frazier's bumper crop

The exits achieved by portfolio companies of Frazier Healthcare in 2011 are another indication that things could be looking up for the venture community and the LPs that fund it. The firm recently reported a...
08:00 , Mar 7, 2011 |  BioCentury  |  Strategy

Metabolic wellspring

In its 2010 annual report, Roche for the first time revealed the $289.6 million price tag it paid to acquire diabetes company Marcadia Biotech Inc. in December. The pharma originally wanted to license Marcadia's first-in-class...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Company News

Marcadia, Roche deal

Roche disclosed in its 2010 annual report that it completed its previously announced acquisition of diabetes and obesity company Marcadia for CHF273 million ($289.6 million) in cash. Marcadia is also eligible for CHF86 million ($91.2...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Company News

Marcadia, Roche deal

The Federal Trade Commission granted early termination to the waiting period under the Hart-Scott-Rodino Act for a proposed acquisition of diabetes and obesity company Marcadia by Roche. Further details were not disclosed. Neither company could...
00:19 , Dec 30, 2010 |  BC Extra  |  Company News

FTC clears Roche acquisition of Marcadia

The Federal Trade Commission granted early termination to the waiting period under the Hart-Scott-Rodino Act for a proposed acquisition of diabetes and obesity company Marcadia Biotech Inc. (Carmel, Ind.) by Roche (SIX:ROG; OTCQX:RHHBY). Further details...
08:00 , Nov 8, 2010 |  BioCentury  |  Finance

Wanted: Less Dilution

The $1 billion in therapeutic tax credit money doled out by the U.S. Treasury last week was spread so thinly among 3,000 companies that biotech CEOs are already looking at ways to make a hoped-for...
07:00 , Oct 25, 2010 |  BioCentury  |  Regulation

Haunted by Byetta

Instead of a relatively small QTc study, Amylin Pharmaceuticals Inc. and Eli Lilly and Co. took a different tack - initially with FDA's blessing - that now looks likely to cost the partners at least...